October 17, 2019 - OutsourcingPharma
Sponsors committed to standardizing data can benefit from ‘more than improved efficiency,’ says YPrime VP, as the company expands its eClinical portfolio to include data standards, clinical analytics and eCOA consulting services.
October 16, 2019 - BioPharma Dive
Alexion Pharmaceuticals is spending $930 million in cash to acquire Achillion Pharmaceuticals, a Pennsylvania-based company developing drugs for some of the same diseases Alexion targets.
Achillion's work revolves around oral inhibitors of Factor D — a regulatory protein found in the alternative complement pathway, which is part of the body's immune system. Achillion's most advanced drug is in mid-stage testing for two rare diseases, paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy, which are also known respectively as PNH and C3G.
October 15, 2019 - Fierce Pharma
Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.
Andrew Dickinson, who joined Gilead in 2016 as EVP of corporate development and strategy, will
assume
the CFO role on Nov. 1, taking over from
retiring
financial chief Robin Washington.
Dickinson orchestrated Gilead’s $11.9 billion acquisition of Kite Pharma in 2017, which marked Gilead’s venture into cancer and cell therapy. And in July, Gilead
splashed
$3.95 billion upfront and $1.1 billion in equity investment for an expanded 10-year R&D pact with Galapagos. The two currently have JAK1 inhibitor filgotinib, which just
came out
of a phase 3 trial in rheumatoid arthritis with flying colors, on the horizon.
October 14, 2019 - Fierce Biotech
BridgeBio Pharma has
scrapped
plans to buy out its subsidiary Eidos Therapeutics. The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.
California-based BridgeBio created Eidos in 2017 to develop AG10, a treatment for the progressive, fatal disease transthyretin amyloidosis. The following year, Eidos went public, leaving BridgeBio with a 66% stake in the startup.
October 14, 2019 - Outsourcing Pharma
With global health care ‘at a tipping point,’ NSF International expands its services across the product lifecycle with the acquisition of a US-headquartered CRO, says VP.
